Literature DB >> 20233657

Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique.

Brian V Balgobind1, Iris H I M Hollink, Dirk Reinhardt, Elisabeth R van Wering, Siebold S N de Graaf, Andre Baruchel, Jan Stary, H Berna Beverloo, Georgine E de Greef, Rob Pieters, C Michel Zwaan, Marry M van den Heuvel-Eibrink.   

Abstract

Mixed-lineage leukaemia (MLL)-partial tandem duplications (PTDs) are found in 3-5% of adult acute myeloid leukaemia (AML), and are associated with poor prognosis. In adult AML, MLL-PTD is only detected in patients with trisomy 11 or internal tandem duplications of FLT3 (FLT3-ITD). To date, studies in paediatric AML are scarce, and reported large differences in the frequency of MLL-PTD, frequently utilising mRNA RT-PCR only to detect MLL-PTDs. We studied the frequency of MLL-PTD in a large cohort of paediatric AML (n=276) and the results from two different methods, i.e. mRNA RT-PCR, and multiplex ligation-dependent probe amplification (MLPA), a method designed to detect copy number differences of specific DNA sequences. In some patients with an MLL-rearrangement, MLL-PTD transcripts were detected, but were not confirmed by DNA-MLPA, indicating that DNA-MLPA can more accurately detect MLL-PTD compared to mRNA RT-PCR. In paediatric AML, MLL-PTD was detected in 7/276 patients (2.5%). One case had a trisomy 11, while the others had normal cytogenetics. Furthermore 4 of the 7 patients revealed a FLT3-ITD, which was significantly higher compared with the other AML cases (p=0.016). In conclusion, using DNA-MLPA as a novel screenings technique in combination with mRNA RT-PCR a low frequency of MLL-PTD in paediatric AML was found. Larger prospective studies are needed to further define the prognostic relevance of MLL-PTD in paediatric AML. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233657     DOI: 10.1016/j.ejca.2010.02.019

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Marry M Van den Heuvel-Eibrink; Renee X De Menezes; Dirk Reinhardt; Iris H I M Hollink; Susan T J C M Arentsen-Peters; Elisabeth R van Wering; Gertjan J L Kaspers; Jacqueline Cloos; Evelien S J M de Bont; Jean-Michel Cayuela; Andre Baruchel; Claus Meyer; Rolf Marschalek; Jan Trka; Jan Stary; H Berna Beverloo; Rob Pieters; C Michel Zwaan; Monique L den Boer
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

Authors:  Norio Shiba; Kenichi Yoshida; Yusuke Hara; Genki Yamato; Yuichi Shiraishi; Hidemasa Matsuo; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Taeko Kaburagi; Masanobu Takeuchi; Kentaro Ohki; Masashi Sanada; Jun Okubo; Daisuke Tomizawa; Tomohiko Taki; Akira Shimada; Manabu Sotomatsu; Keizo Horibe; Takashi Taga; Souichi Adachi; Akio Tawa; Satoru Miyano; Seishi Ogawa; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2019-10-22

3.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

4.  Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.

Authors:  Brian V Balgobind; Iris H I M Hollink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Jochen Harbott; H Berna Beverloo; Anne R M von Bergh; Jacqueline Cloos; Gertjan J L Kaspers; Valerie de Haas; Zuzana Zemanova; Jan Stary; Jean-Michel Cayuela; Andre Baruchel; Ursula Creutzig; Dirk Reinhardt; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

Review 5.  Acute myeloid leukemia in infants: biology and treatment.

Authors:  Riccardo Masetti; Francesca Vendemini; Daniele Zama; Carlotta Biagi; Andrea Pession; Franco Locatelli
Journal:  Front Pediatr       Date:  2015-04-28       Impact factor: 3.418

Review 6.  Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.

Authors:  Vincenza Ylenia Cusenza; Alessandra Bisagni; Monia Rinaldini; Chiara Cattani; Raffaele Frazzi
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

7.  Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.

Authors:  Taeko Kaburagi; Genki Yamato; Norio Shiba; Kenichi Yoshida; Yusuke Hara; Ken Tabuchi; Yuichi Shiraishi; Kentaro Ohki; Manabu Sotomatsu; Hirokazu Arakawa; Hidemasa Matsuo; Akira Shimada; Tomohiko Taki; Nobutaka Kiyokawa; Daisuke Tomizawa; Keizo Horibe; Satoru Miyano; Takashi Taga; Souichi Adachi; Seishi Ogawa; Yasuhide Hayashi
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.